258.42MMarket Cap-1881P/E (TTM)
4.170High3.900Low348.09KVolume4.020Open3.980Pre Close1.42MTurnover0.67%Turnover RatioLossP/E (Static)62.72MShares21.88052wk High4.47P/B213.01MFloat Cap2.95152wk Low--Dividend TTM51.70MShs Float41.000Historical High--Div YieldTTM6.79%Amplitude2.130Historical Low4.074Avg Price1Lot Size
Macrogenics Stock Forum
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
MacroGenics (NASDAQ: MGNX) presented updated efficacy and safety results from the TAMARACK Phase 2 study of vobramitamab duocarmazine(vobra duo) for metastatic castration-resistant prostate cancer (mCRPC) at the ESMO Congress 2024.
Key findings include:
▪️6-month radiographic progression-free survival (rPFS) rate: 69% for 2.0 mg...
MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
MacroGenics (NASDAQ: MGNX) announced a poster presentation of Phase 2 data for vobramitamab duocarmazine in metastatic castration-resistant prostate cancer (mCRPC) at the ESMO Congress 2024. The TAMARACK trial results will be presented on September 15, 2024, featuring updated safety and efficacy data, including the primary endpoint of 6-month radiographic progression-free survival (rPFS).
Th...
f@#$%^&* up
MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration With Incyte
MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte
No comment yet